Squarepoint Ops LLC Boosts Stake in BeOne Medicines Ltd. – Sponsored ADR $ONC

Squarepoint Ops LLC increased its stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 6.0% during the second quarter, Holdings Channel.com reports. The firm owned 78,561 shares of the company’s stock after purchasing an additional 4,437 shares during the quarter. Squarepoint Ops LLC’s holdings in BeOne Medicines were worth $22,388,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Baird Financial Group Inc. lifted its stake in shares of BeOne Medicines by 5.5% during the 2nd quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock valued at $105,148,000 after buying an additional 19,327 shares in the last quarter. Nykredit A S purchased a new stake in BeOne Medicines in the 2nd quarter worth $1,204,000. Corient Private Wealth LP raised its holdings in BeOne Medicines by 12.6% during the second quarter. Corient Private Wealth LP now owns 1,132 shares of the company’s stock valued at $323,000 after acquiring an additional 127 shares during the period. AXQ Capital LP bought a new stake in BeOne Medicines during the second quarter valued at about $201,000. Finally, B. Metzler seel. Sohn & Co. AG lifted its position in shares of BeOne Medicines by 73.5% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 6,706 shares of the company’s stock valued at $1,911,000 after acquiring an additional 2,840 shares in the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at BeOne Medicines

In other news, CEO John Oyler sold 145,861 shares of the business’s stock in a transaction on Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the sale, the chief executive officer directly owned 8,122 shares of the company’s stock, valued at approximately $2,484,925.90. The trade was a 94.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 579,683 shares of company stock worth $190,541,846. 6.19% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ONC has been the topic of a number of research analyst reports. Leerink Partners boosted their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. TD Cowen lifted their price objective on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a research report on Monday, July 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $402.14.

BeOne Medicines Price Performance

NASDAQ:ONC opened at $351.48 on Wednesday. The firm has a market capitalization of $38.59 billion, a price-to-earnings ratio of 61.88 and a beta of 0.51. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. The business has a 50 day simple moving average of $336.64 and a 200-day simple moving average of $311.42. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The business had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.66 billion. Equities analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 EPS for the current year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.